Review
Oncology
Oluwatobi Odetola, Shuo Ma
Summary: This review emphasizes that the purpose of treatment for relapsed/refractory CLL is disease control and delay of progression rather than cure. The article reviews the concept of relapsed CLL, factors predisposing to relapse, and available therapeutic options. Recent findings show that targeted therapies such as continuous BTK inhibitors or fixed duration venetoclax plus anti-CD20 monoclonal antibody therapy have established superiority over chemoimmunotherapy in relapsed CLL and are now the preferred standard of care treatment.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
(2023)
Review
Oncology
Matthew Karr, Lindsey Roeker
Summary: The treatment landscape for CLL has been revolutionized by the introduction of targeted therapies, which have demonstrated superior outcomes in terms of PFS and OS when compared to chemoimmunotherapy. Targeted agents, such as ibrutinib, acalabrutinib, zanubrutinib, and venetoclax, have become the new standard of care and are effective irrespective of high-risk mutational status.
Article
Oncology
Yanping Yin, Paschalis Athanasiadis, Linda Karlsen, Aleksandra Urban, Haifeng Xu, Ishwarya Murali, Stacey M. Fernandes, Alberto J. Arribas, Abdul K. Hilli, Kjetil Tasken, Francesco Bertoni, Anthony R. Mato, Emmanuel Normant, Jennifer R. Brown, Geir E. Tjonnfjord, Tero Aittokallio, Sigrid S. Skanland
Summary: This study analyzes the activity and cellular effects of PI3K inhibitors in CLL, finds novel treatment vulnerabilities, and suggests that ex vivo functional profiling can stratify PI3Ki responders.
CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Yu Nie, Xiaoya Yun, Ya Zhang, Xin Wang
Summary: Metabolic reprogramming plays a vital role in the initiation and progression of chronic lymphocytic leukemia (CLL). This review summarizes the critical metabolic processes in CLL and discusses the regulation of metabolism by cells in the microenvironment and oncogenes/tumor suppressor regulators. Targeting metabolic enzymes or signal pathways may impede the progression of CLL.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2022)
Article
Medicine, General & Internal
Tanya Siddiqi, David G. Maloney, Saad S. Kenderian, Danielle M. Brander, Kathleen Dorritie, Jacob Soumerai, Peter A. Riedell, Nirav N. Shah, Rajneesh Nath, Bita Fakhri, Deborah M. Stephens, Shuo Ma, Tatyana Feldman, Scott R. Solomon, Stephen J. Schuster, Serena K. Perna, Sherilyn A. Tuazon, San -San Ou, Eniko Papp, Leanne Peiser, Yizhe Chen, William G. Wierda
Summary: In this study, lisocabtagene maraleucel (liso-cel) was evaluated for its efficacy and safety in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The results showed that liso-cel induced complete response or remission in patients, including those who had previously failed treatment with a BTK inhibitor and venetoclax. The safety profile was manageable.
Article
Hematology
Martin Simkovic, Peter Turcsanyi, Martin Spacek, Jana Mihalyova, Pavlina Ryznerova, Maria Maco, Pavel Vodarek, Dominika Ecsiova, Hynek Poul, Heidi Mocikova, Jana Zuchnicka, Anna Panovska, Mohammad Lekaa, Martina Orsulova, Adela Prchlikova, Lukas Stejskal, Stanislava Maslejova, Yvona Brychtova, Lucie Bezdekova, Tomas Papajik, Daniel Lysak, Marek Trneny, Lukas Smolej, Michael Doubek
Summary: This study evaluated the impact of COVID-19 infection on CLL patients in the Czech Republic. The results showed that CLL patients who were infected with COVID-19 had a higher risk of death, and there were certain factors associated with the increased risk of death, such as age, gender, and treatment history.
ANNALS OF HEMATOLOGY
(2023)
Article
Oncology
Nitin Jain, Philip Thompson, Jan Burger, Alessandra Ferrajoli, Koichi Takahashi, Zeev Estrov, Gautam Borthakur, Prithviraj Bose, Tapan Kadia, Naveen Pemmaraju, Koji Sasaki, Marina Konopleva, Elias Jabbour, Naveen Garg, Xuemei Wang, Rashmi Kanagal-Shamanna, Keyur Patel, Wei Wang, Jeffrey Jorgensen, Sa Wang, Wanda Lopez, Ana Ayala, William Plunkett, Varsha Gandhi, Hagop Kantarjian, Susan O'Brien, Michael Keating, William G. Wierda
Summary: The iFCG regimen with only 3 cycles of chemotherapy is an effective, time-limited regimen for patients with CLL with mutated IGHV and without del(17p)/TP53 mutation. The treatment resulted in high rates of complete remission and undetectable measurable residual disease in the marrow, with excellent 3-year progression-free and overall survival rates.
Review
Medicine, General & Internal
Mazyar Shadman
Summary: Chronic lymphocytic leukemia is an immunocompromised blood cancer that can be treated with targeted agents like BTK inhibitors or BCL2 inhibitors, but currently there is no cure for the disease.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Biology
Mohammad Almasri, Marah Amer, Joseph Ghanej, Abdurraouf Mokhtar Mahmoud, Gianluca Gaidano, Riccardo Moia
Summary: Chronic lymphocytic leukemia (CLL), the most common type of leukemia in adults, has achieved significant breakthroughs in treatment management mainly through targeted therapy to overcome high-risk genetic features and chemoresistance.
Article
Biochemistry & Molecular Biology
Kristan V. Piroeva, Charlotte Mcdonald, Charalampos Xanthopoulos, Chelsea Fox, Christopher T. Clarkson, Jan-Philipp Mallm, Yevhen Vainshtein, Luminita Ruje, Lara C. Klett, Stephan Stilgenbauer, Daniel Mertens, Efterpi Kostareli, Karsten Rippe, Vladimir B. Teif
Summary: This study compared the nucleosome positions in chronic lymphocytic leukemia (CLL) patients and healthy individuals, and found significant changes in nucleosome positioning in CLL. The spacing between nucleosomes was shortened, and changes in nucleosome occupancy were linked to chromatin remodeling and reduced DNA methylation. Nucleosome positioning can be used to classify CLL subtypes and monitor disease progression.
Article
Medicine, General & Internal
Diliara Bagautdinova, Kelsey C. Bacharz, Carma L. Bylund, Maria Sae-Hau, Elisa S. Weiss, Michelle Rajotte, Greg Lincoln, Taylor S. Vasquez, Naomi D. Parker, Kevin B. Wright, Carla L. Fisher
Summary: Chronic lymphocytic leukemia (CLL) caregivers continue to face challenges in coping with distress, living in isolation, and losing in-person care opportunities during the COVID-19 pandemic. They experience increasing caregiving burden and deal with unsupportive/skeptical individuals. CLL caregivers need reliable information about COVID-19 risk, vaccination, safety measures, and monoclonal infusions. This study highlights the ongoing challenges and provides an agenda for better supporting CLL caregivers during the pandemic.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Anna Puiggros, Silvia Ramos-Campoy, Joanna Kamaso, Mireia de la Rosa, Marta Salido, Carme Melero, Maria Rodriguez-Rivera, Sandrine Bougeon, Rosa Collado, Eva Gimeno, Rocio Garcia-Serra, Sara Alonso, Marco Antonio Moro-Garcia, Maria Dolores Garcia-Malo, Xavier Calvo, Leonor Arenillas, Ana Ferrer, Tuomo Mantere, Alexander Hoischen, Jacqueline Schoumans, Blanca Espinet
Summary: This study investigated the use of optical genome mapping (OGM) in assessing the cytogenetics of chronic lymphocytic leukemia (CLL). The results showed that OGM can identify most known abnormalities and provide new structural information. OGM had better accuracy than current methods in predicting the time to first treatment. A complex OGM group defined by the number of abnormalities was associated with TP53 abnormalities and shorter time to first treatment.
Article
Oncology
Iwona Hus, Bartosz Pula, Tadeusz Robak
Summary: The development of small agents targeting the B-cell receptor (BCR) pathway has greatly improved the treatment of chronic lymphocytic leukemia (CLL). Selective inhibitors of PI3K delta, such as idelalisib and duvelisib, have been approved for CLL treatment. Umbralisib, a selective inhibitor of PI3K delta and CK1 epsilon, has shown promising results in combination regimens in clinical trials for CLL treatment.
Article
Oncology
O. Al-Sawaf, S. Robrecht, J. Bahlo, A. M. Fink, P. Cramer, J. Von Tresckow, E. Lange, M. Kiehl, M. Dreyling, M. Ritgen, J. Duerig, E. Tausch, C. Schneider, S. Stilgenbauer, C. M. Wendtner, K. Fischer, V Goede, M. Hallek, B. Eichhorst
Summary: Richter transformation (RT) is the development of aggressive lymphoma in patients with CLL, with an incidence rate ranging from 2% to 10%. In a study of GCLLSG trial participants, 3% of patients developed RT, mostly diffuse large B-cell lymphoma. Patients with RT had a significantly shorter overall survival compared to those without RT.
Review
Oncology
Max Yano, John C. Byrd, Natarajan Muthusamy
Summary: This article reviews the potential and progress of NK cell therapy for CLL, highlighting the immunosuppressive effects of CLL on NK cells as a major limitation to the development of effective treatments. Despite the challenges, NK cell therapy still holds significant therapeutic potential for CLL.
Letter
Oncology
Gabriela Galicia-Vazquez, Sarah Smith, Raquel Aloyz
BLOOD CANCER JOURNAL
(2018)
Article
Oncology
Bahram Sharif-Askari, Lilian Amrein, Raquel Aloyz, Lawrence Panasci
BREAST CANCER RESEARCH AND TREATMENT
(2018)
Review
Oncology
Gabriela Galicia-Vazquez, Raquel Aloyz
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2019)
Article
Multidisciplinary Sciences
Bahram Sharif-Askari, Daniel Doyon, Miltiadis Paliouras, Raquel Aloyz
SCIENTIFIC REPORTS
(2019)
Article
Oncology
Sarit Assouline, Lilian Amrein, Raquel Aloyz, Versha Banerji, Stephen Caplan, Carolyn Owen, Wanda Hasegawa, Sue Robinson, Sudeep Shivakumar, Anca Prica, Anthea Peters, Linda Hagerman, Laura Rodriguez, Tanya Skamene, Lawrence Panasci, Bingshu E. Chen, Annette E. Hay
LEUKEMIA & LYMPHOMA
(2020)
Article
Chemistry, Analytical
Sahar Ibrahim, Bjoern C. Froehlich, Adriana Aguilar-Mahecha, Raquel Aloyz, Oliver Poetz, Mark Basik, Gerald Batist, Rene P. Zahedi, Christoph H. Borchers
ANALYTICAL CHEMISTRY
(2020)
Article
Psychiatry
Ibrahim Turkoz, Larry Alphs, Jaskaran Singh, Carol Jamieson, Ella Daly, May Shawi, John J. Sheehan, Madhukar H. Trivedi, A. John Rush
Summary: Using the CGI-S scale, this study identified clinically meaningful and substantial changes in the MADRS, SDS, and PHQ-9 scores for patients with treatment-resistant depression. Clinically meaningful changes corresponded to 6-, 4-, and 3-point changes from baseline on the MADRS, SDS, and PHQ-9, while clinically substantial changes corresponded to 12-, 8-, and 6-point changes. The ESK plus OAD group showed a higher proportion of patients with substantial clinical improvement compared to the OAD plus PBO group after 28 days of treatment.
ACTA PSYCHIATRICA SCANDINAVICA
(2021)
Article
Health Care Sciences & Services
Urvi Desai, Noam Y. Kirson, Andrea Guglielmo, Hoa H. Le, Timothy Spittle, Joshua Tseng-Tham, May Shawi, John J. Sheehan
Summary: The study found that esketamine nasal spray plus an oral antidepressant (ESK + oral AD) is a cost-efficient alternative treatment for treatment-resistant depression compared to oral AD plus nasal placebo (oral AD + PBO), offering better clinical outcomes at a slightly higher cost.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
(2021)
Article
Rheumatology
Dennis McGonagle, Iain B. McInnes, Atul Deodhar, Georg Schett, May Shawi, Shelly Kafka, Chetan S. Karyekar, Alexa P. Kollmeier, Elizabeth C. Hsia, Xie L. Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Christopher T. Ritchlin, Proton Rahman, Philip J. Mease
Summary: The study confirmed the efficacy of guselkumab in treating enthesitis, especially in resolving enthesitis and improving disease activity in patients. The results showed that guselkumab could continuously improve the condition of enthesitis and may have a positive impact on patient outcomes.
Meeting Abstract
Oncology
Parvaneh Fallah, Nasser Khleel Mulla, Raquel Aloyz, Olga Aleynikova, Anca Florea, Manuela Pelmus, Lawrence C. Panasci
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Rheumatology
Laura C. Coates, Laure Gossec, Elke Theander, Paul Bergmans, Marlies Neuhold, Chetan S. Karyekar, May Shawi, Wim Noel, Georg Schett, Iain B. McInnes
Summary: The study demonstrated that guselkumab significantly improved joint and skin manifestations as well as physical function in patients with TNFi-IR PsA. A higher proportion of patients in the guselkumab group achieved ACR20 and other key secondary endpoints compared to the placebo group, with 58% of ACR20 response in the guselkumab group at week 48.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Iain B. McInnes, Proton Rahman, Alice B. Gottlieb, Elizabeth C. Hsia, Alexa P. Kollmeier, Xie L. Xu, Yusang Jiang, Shihong Sheng, May Shawi, Soumya D. Chakravarty, Desiree van der Heijde, Philip J. Mease
Summary: In patients with active psoriatic arthritis, guselkumab provided durable improvements in multiple disease domains over a 2-year period with no unexpected safety findings.
ARTHRITIS & RHEUMATOLOGY
(2022)
Article
Rheumatology
Proton Rahman, Philip J. Mease, Philip S. Helliwell, Atul Deodhar, Laure Gossec, Arthur Kavanaugh, Alexa P. Kollmeier, Elizabeth C. Hsia, Bei Zhou, Xiwu Lin, May Shawi, Chetan S. Karyekar, Chenglong Han
Summary: In patients with active psoriatic arthritis, the interleukin-23p19-subunit inhibitor guselkumab led to clinically meaningful and sustained improvements in fatigue through one year. Substantial portion of the improvement in fatigue scores induced by guselkumab was independent of effects on the achievement of other select outcomes.
ARTHRITIS RESEARCH & THERAPY
(2021)
Article
Rheumatology
Christopher T. Ritchlin, Philip S. Helliwell, Wolf-Henning Boehncke, Enrique R. Soriano, Elizabeth C. Hsia, Alexa P. Kollmeier, Soumya D. Chakravarty, Federico Zazzetti, Ramanand A. Subramanian, Xie L. Xu, Qing C. Zuraw, Shihong Sheng, Yusang Jiang, Prasheen Agarwal, Bei Zhou, Yanli Zhuang, May Shawi, Chetan S. Karyekar, Atul Deodhar
Summary: The study demonstrated that guselkumab provided sustained improvement in patients with Psoriatic Arthritis, maintaining a favorable benefit-risk profile regardless of prior TNFi exposure.
Article
Clinical Neurology
Carmela Benson, David Singer, Colleen M. Carpinella, May Shawi, Larry Alphs
Summary: This study revealed that patients with higher levels of suicidal ideation in the context of moderately severe/severe MDD had lower HRQoL, greater HRU, and more work impairment, resulting in higher direct and indirect costs compared to patients with MDD but no suicidal ideation.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2021)